Novo Nordisk, Eli Lilly Report GLP-1 Signals of Slowed Biological Aging at ARDD

Novo Nordisk and Eli Lilly presented early data at the ARDD conference suggesting that GLP-1 receptor agonists like semaglutide and tirzepatide may slow biological aging. Clinical readouts indicate potential improvements in molecular aging clocks across various tissues.
Why it matters
This could shift the perception of weight-loss drugs from purely metabolic treatments to potential longevity-extending therapies.
Oct 4, 2026 | 6 min read Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit Key Insights Novo Nordisk View company profile and Eli Lilly View company profile presented early data at the ARDD conference suggesting semaglutide View drug details and tirzepatide View drug details may slow molecular measures of biological aging.
Novo reported proteomic clock differences of roughly two to three years, with up to four years on a clock tracking heart proteins, in a 10,052-person study.
Lilly's epigenetic sub-study within SURMOUNT-5 found all 15 age-unit clocks showed less aging than the 1.38 years of elapsed chronological time.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in